Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant osimertinib versus placebo in EGFR-mutant stage IA2–IA3 NSCLC after complete resection
2021-004135-89Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Osimertinib with Placebo (2 arms). Primary endpoint: Disease-free survival in high-risk stratum. Started Dec 2021; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-004135-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004135-89.